M Ventures Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 18
- Investments
- 126
- Portfolio
- 58
- Exits
- 21
M Ventures General Information
Description
Founded in 2009, M Ventures is the strategic, corporate venture capital arm of Merck KGaA and is headquartered in Amsterdam, Netherlands. The firm also has offices in Darmstadt, Germany, Cambridge, Massachusetts, and Yavne, Israel. The firm seeks to invest in seed and early-stage companies operating in healthcare, electronics, life sciences, performance materials, and other new businesses, in alignment with the strategic interests of Merck KGaA.
Contact Information
Website
www.m-ventures.com
Year Founded
2009
Investor Status
Actively Seeking New Investments
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Accelerator/Incubator
Primary Office
- Gustav Mahlerplein 102
- Toyo lto Building, 20th Floor
- 1082 MA Amsterdam
- Netherlands
M Ventures Investments (126)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Plexium | 23-Feb-2022 | Later Stage VC | 00000 | Drug Discovery | Generating Revenue | |
| 000000000 00 | 04-Feb-2022 | 00000 00000 | 0000 | Application Specific Semiconductors | Stealth | |
| 000000 000000000 | 06-Jan-2022 | 00000 00000 | 00.000 | Diagnostic Equipment | Generating Revenue | 0000000 0000000000000 00.0 |
| 00000000 000000000 | 29-Dec-2021 | 00000 00000 | 000.00 | Electronic Equipment and Instruments | Generating Revenue | |
| 000000 00000000000 | 01-Dec-2021 | 00000 00000 | Other Healthcare Technology Systems | Startup | ||
| 00000000000 | 01-Dec-2021 | 00000 00000 | Other Healthcare Technology Systems | Generating Revenue | ||
| 000 000000 | 26-Oct-2021 | 00000 00000 | 00000 | Biotechnology | Generating Revenue | |
| 0000 000000000000 | 05-Oct-2021 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | |
| Formo | 13-Sep-2021 | Early Stage VC | 0000 | Food Products | Generating Revenue | 000000000 00000000 |
| Biolinq | 02-Sep-2021 | Later Stage VC | 00000 | Monitoring Equipment | Product In Beta Test |
M Ventures Exits (21)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Forendo Pharma | 13-Dec-2021 | Merger/Acquisition | 00000 |
| 00000 000000000000 | 22-Oct-2021 | 000 | 00000 |
| 00000000 000000000 | 16-Sep-2021 | 000 00 00000000 | |
| 0000000 000 0 | 10-Feb-2021 | 000 00 00000000 | |
| 0-0000 00000000000 | 20-Nov-2020 | 0000000 000000 | |
| 0000000 | 25-Oct-2019 | 000 | 00000 |
| 000000000 | 01-Jan-2019 | 000 00 00000000 | |
| 000000000 000 | 28-Jun-2018 | 000 | 00000 |
| Artsavit | 01-Jun-2018 | Out of Business | |
| Prexton Therapeutics | 16-Mar-2018 | Merger/Acquisition | 00000 |
M Ventures Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialM Ventures Team (79)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Javier Rodriguez | Chief Financial Officer | Darmstadt, Germany | |||
| Hakan Goker Ph.D | Managing Director Biotechnology | 00 | 0 | 0 | Amsterdam, Netherlands |
| Christian Patze Ph.D | Investment Principal Technology | 0 | 0 | 0 | Cambridge, MA |
| Wallace LE Wallace | Investment Associate Biotechnology | Amsterdam, Netherlands | |||
| Sarah Luppino Ph.D | Investment Associate Technology | Amsterdam, Netherlands |
M Ventures Co-Investors (286)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Novartis Venture Fund | 5 | 0 | 0 |
|
|
| Alexandria Venture Investments | 0 | 0 |
|
|
|
| Pfizer Ventures | 0 | 0 |
|
|
|
| Applied Ventures | 0 | 0 |
|
|
|
| IP Group | 0 | 0 |
|
|